Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 15, 2021

SuperTrans appoints Australian firms for new drug trials to fight AMR

SuperTrans Medical has appointed Australian companies CMAX, Avance Clinical, and Agilex Biolabs for clinical trial research of a new drug in the battle against antimicrobial resistance (AMR).

SuperTrans Medical has appointed Australian companies CMAX, Avance Clinical, and Agilex Biolabs for clinical trial research of a new drug in the battle against antimicrobial resistance (AMR).

The World Health Organization (WHO) describes AMR as a ‘silent pandemic’ and one of the biggest threats to global health.

CMAX, Avance Clinical and Agilex Biolabs will serve as SuperTrans Medical’s key clinical research partners for conducting the launch of Phase I human clinical trials in Australia this year for the company’s new antibiotic.

The drug makes use of SuperTrans Medical’s Intelligent Repurposing technology, which was invented at Stanford University originally.

SuperTrans Medical CEO Dr Lewis Neville said: “Antibiotic-resistant infections are a serious threat to global health and with only four new classes of antibiotics introduced since the early 1960s, clinicians just don’t have enough to work with.

“With the highly promising safety and efficacy results we’ve seen to date, we believe our repurposed and retargeted antibiotic could bring a much-needed and new panacea to thwart these urgent threat pathogens.”

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

Recently, the company announced plans to start clinical trials in the country later this year for its lead indication, complicated Urinary Tract Infections (cUTIs), which represent one of the most frequent infectious diseases.

South Australia Trade and Investment Minister Stephen Patterson said: “Within the plan, clinical trials have been identified by industry as a key enabler for growth, and today’s announcement is a major win for the state, highlighting the vast opportunities in this fast-growing sector.”

CMAX will be responsible for the preparation and carrying out of the Phase I study at Royal Adelaide Hospital.

All the activities surrounding this trial will be managed and coordinated by Avance Clinical, and Agilex Biolabs would provide all the required bioanalytical services and support associated with it.

SuperTrans Medical’s clinical trial will start in healthy volunteers late this year in Australia.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU